Agenus appoints BAP Pharma as global partner for BOT+BAL access programs

Agenus (AGEN) and BAP Pharma announced the exclusive appointment of BAP Pharma as Agenus’ global partner for botensilimab plus balstilimab authorized global access programs. The partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations. Effective immediately, BAP Pharma will serve as Agenus’ exclusive partner for the coordination of BOT+BAL global access program operations, including program requests, case coordination, distribution logistics, and related payment processing. These programs include France’s Autorisation d’Acces Compassionnel pathway as well as paid named-patient programs in select countries outside the United States. As previously disclosed, Agenus has received more than 270 physician inquiries from more than 30 countries across these pathways. Under the collaboration, BAP Pharma will coordinate Agenus’ global access operations across these programs. BAP Pharma brings extensive global medicines access experience, a professional and responsive approach to physician and site engagement, and the operational rigor required to streamline logistics, strengthen regional coordination, and support treating physicians navigating country-specific regulatory frameworks.